[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367251-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367251-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-potential-applications-of-peptide-loading-complex-in-cancer-treatment","The potential applications of peptide-loading complex in cancer treatment","","Cancer immunotherapy has advanced rapidly, improving outcomes especially in hematological malignancies, yet translating these gains to solid tumors remains difficult. This review focuses on the peptide-loading complex (PLC), a temporary ER multisubunit assembly required to initiate hierarchical immune responses by coordinating peptide loading and editing onto MHC-I. It explains how PLC components support T-cell priming and differentiation, and how MHC-I changes contribute to immune escape, including resistance to T-cell–based therapies. The article evaluates PLC functions across cancer types to inform better treatment strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-potential-applications-of-peptide-loading-complex-in-cancer-treatment/367251/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-potential-applications-of-peptide-loading-complex-in-cancer-treatment/367251.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does the peptide-loading complex (PLC) play in cancer immunotherapy?","Question",{"text":63,"@type":64},"The PLC coordinates peptide translocation, loading, and editing on MHC-I in the endoplasmic reticulum, which is crucial for initiating immune responses and supporting T-cell functions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is targeting solid tumors more challenging than hematological cancers?",{"text":68,"@type":64},"Although immunotherapies improve outcomes in hematological diseases, translating those benefits to solid tumors has been difficult, partly because effective immune recognition and processing can be disrupted.",{"name":70,"@type":61,"acceptedAnswer":71},"How can changes in MHC molecule expression enable tumor immune escape?",{"text":72,"@type":64},"Tumors can evade immunity by altering MHC expression; decreased MHC-I levels reduce antigen presentation to T-lymphocytes and can be linked to resistance against T-cell–based therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367251,1790244346,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":113,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","TYPE Review  \nPUBLISHED 03 March 2025  \nDOI 10.3389/fimmu.2025.1526137  \nOPEN ACCESS  \nEDITED BY  \nSonja Ludwig,  \nUniversity of Heidelberg, Germany  \nREVIEWED BY  \nKiran Kundu,  \nUniversity of Texas MD Anderson Cancer Center, United States  \nZhijian Huang,  \nFujian Medical University, China Marco Cavaco,  \nUniversidade de Lisboa, Portugal  \n*CORRESPONDENCE  \nJiaxin You  \n [youjx@jlu.edu.cn](youjx@jlu.edu.cn)  \nRECEIVED 11 November 2024  \nACCEPTED 05 February 2025  \nPUBLISHED 03 March 2025  \nCITATION  \nSong Z, Tao Y and You J (2025) The potential applications of peptideloading complex in cancer treatment.  \nFront. Immunol. 16:1526137 .  \ndoi: 10.3389/fimmu.2025.1526137  \nCOPYRIGHT  \n© 2025 Song, Tao and You. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe potential applications of peptide-loading complex in cancer treatment  \nZhidu Song 1, Ying Tao 2 and Jiaxin You 1*  \n1 Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, China,  \n2 Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun, China  \nImmunotherapy for cancer has made signiﬁcant strides in the last several years. The prognosis for cancer patients has signiﬁcantly improved as a result, particularly in hematological diseases . However, it was discovered that translating these achievements to solid tumors proved challenging. The peptide-loading complex (PLC), a temporary multisubunit membrane assembly in the endoplasmic reticulum (ER), is crucial for initiating a hierarchical immune response. Chaperones calreticulin and tapasin make up the PLC, unique to class I glycoproteins, thiooxido-reductase ERp57, and a transporter associated with antigen processing. The loading and editing of major histocompatibility complex class I (MHC-I) molecules with peptide translocation into the ER are synchronized by the PLC. One of the immune escape strategies revealed for tumors so far is changes in the expression of MHC molecules. This is because MHC antigens are crucial in presenting antigens to T-lymphocytes and controlling NK cell activity. Furthermore, decreased MHC-I expression has been linked to malignancies resistant to T-cell-based cancer immunotherapies (adoptive transfer of antitumor CD8 T-cells or checkpoint inhibition) . The PLC is essential for T-cell priming, differentiation, and tumor growth control because it can bind to a wide range of MHC-I allomorphs. In this review, we have looked into PLC ’s function and effects in all forms of cancer to improve cancer therapy techniques.  \nKEYWORDS  \npeptide-loading complex, cancer, immunotherapy, major histocompatibility complex (MHC), cancer vaccine, treatment  \n1 Introduction  \nCancer affects people of all ages, socioeconomic levels, and ethnicities, making it a global health threat (1, 2) . Cancer treatments include hormone therapy, radiation, chemotherapy, and surgical excision of the cancerous tissue (3) . One popular method of treating cancer is chemotherapy, which involves the systemic administration of anticancer medications to patients to slow the unchecked growth of cancer cells (4) . The effectiveness of immune checkpoint inhibitors in treating lung cancer (LC) (5) and melanoma (6) has sparked research into immunotherapy for a variety of tumor forms, including breast cancer  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n(BC) (7) . However, these trials have shown only a modest clinical beneﬁt in many scenarios (8, 9) . Therefore, to develop innovative treatment approaches that boost antitumor immunity in more resistant tumors, it is cruci","cbCailtPmhqYRSTU","https://ap.wps.com/l/cbCailtPmhqYRSTU","pdf",1588762,"English","# Introduction\n## Immunotherapy progress and challenges in solid tumors\n## T-cell antigen discovery and epitope identification limitations\n## Immune regulation and structural approaches for treatment optimization","[{\"question\":\"What role does the peptide-loading complex (PLC) play in cancer immunotherapy?\",\"answer\":\"The PLC coordinates peptide translocation, loading, and editing on MHC-I in the endoplasmic reticulum, which is crucial for initiating immune responses and supporting T-cell functions.\"},{\"question\":\"Why is targeting solid tumors more challenging than hematological cancers?\",\"answer\":\"Although immunotherapies improve outcomes in hematological diseases, translating those benefits to solid tumors has been difficult, partly because effective immune recognition and processing can be disrupted.\"},{\"question\":\"How can changes in MHC molecule expression enable tumor immune escape?\",\"answer\":\"Tumors can evade immunity by altering MHC expression; decreased MHC-I levels reduce antigen presentation to T-lymphocytes and can be linked to resistance against T-cell–based therapies.\"}]","The potential applications of peptide-loading complex in cancer treatment | PDF",1790169910,76,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7808630fcfe2bee4fe888da1839060ab.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0910e51e5fc6f7b778392adad7b8d9de.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4e0678c7011c821a107a6560f93048e.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52b1c111fe0e394424d723b68c75b44b.webp",980,1385]